Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5093600
Max Phase: Preclinical
Molecular Formula: C43H53N7O9S
Molecular Weight: 844.00
Molecule Type: Unknown
Associated Items:
ID: ALA5093600
Max Phase: Preclinical
Molecular Formula: C43H53N7O9S
Molecular Weight: 844.00
Molecule Type: Unknown
Associated Items:
Canonical SMILES: Cc1ncsc1-c1ccc(CNC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@@H](NC(=O)COCCOCCOCC(=O)Nc2ccc(C(=O)Nc3ccccc3N)cc2)C(C)(C)C)cc1
Standard InChI: InChI=1S/C43H53N7O9S/c1-27-38(60-26-46-27)29-11-9-28(10-12-29)22-45-41(55)35-21-32(51)23-50(35)42(56)39(43(2,3)4)49-37(53)25-59-20-18-57-17-19-58-24-36(52)47-31-15-13-30(14-16-31)40(54)48-34-8-6-5-7-33(34)44/h5-16,26,32,35,39,51H,17-25,44H2,1-4H3,(H,45,55)(H,47,52)(H,48,54)(H,49,53)/t32-,35+,39-/m1/s1
Standard InChI Key: MNUQUYIPHCWRAK-MNYREFGISA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 844.00 | Molecular Weight (Monoisotopic): 843.3625 | AlogP: 3.75 | #Rotatable Bonds: 19 |
Polar Surface Area: 223.54 | Molecular Species: NEUTRAL | HBA: 12 | HBD: 6 |
#RO5 Violations: 3 | HBA (Lipinski): 16 | HBD (Lipinski): 7 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 11.95 | CX Basic pKa: 3.24 | CX LogP: 1.58 | CX LogD: 1.58 |
Aromatic Rings: 4 | Heavy Atoms: 60 | QED Weighted: 0.06 | Np Likeness Score: -0.88 |
1. Smalley JP, Baker IM, Pytel WA, Lin LY, Bowman KJ, Schwabe JWR, Cowley SM, Hodgkinson JT.. (2022) Optimization of Class I Histone Deacetylase PROTACs Reveals that HDAC1/2 Degradation is Critical to Induce Apoptosis and Cell Arrest in Cancer Cells., 65 (7.0): [PMID:35293758] [10.1021/acs.jmedchem.1c02179] |
Source(1):